Can-Fite BioPharma Ltd.: financial reference
Explore Can-Fite BioPharma Ltd. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.
Context from the filing
For 2023–2025, Can-Fite’s filing already gives retrospective effect to its share splits in the presented ordinary-share and per-share figures. The January 2026 1-for-3,000 ordinary-share reverse split is distinct from the ADS ratio change from 300 to two ordinary shares per ADS. The selected figures remain ordinary-share measures; no second split adjustment or ADS conversion is applied. Outstanding options and warrants are excluded as anti-dilutive for all presented periods. Shares and EPS retain scale-zero tags under the share/per-share exception to the thousands heading. Read the source filing.
Reported financial histories
Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.
| Measure | Period start | Period end | Value | Unit | Filed |
|---|---|---|---|---|---|
| Total assets | At date | 2025-12-31 | 9,514,000 | USD | 2026-03-26 |
| Stockholders equity | At date | 2025-12-31 | 5,592,000 | USD | 2026-03-26 |
| Cash and cash equivalents | At date | 2025-12-31 | 5,528,000 | USD | 2026-03-26 |
| Net income or loss | 2025-01-01 | 2025-12-31 | -9,828,000 | USD | 2026-03-26 |
| Operating cash flow | 2025-01-01 | 2025-12-31 | -8,949,000 | USD | 2026-03-26 |
| Capital expenditure payments | 2025-01-01 | 2025-12-31 | 2,000 | USD | 2026-03-26 |
| Revenue | 2025-01-01 | 2025-12-31 | 405,000 | USD | 2026-03-26 |
| Financing cash flow | 2025-01-01 | 2025-12-31 | 9,644,000 | USD | 2026-03-26 |
| Investing cash flow | 2025-01-01 | 2025-12-31 | -2,000 | USD | 2026-03-26 |
| Retained earnings or deficit | At date | 2025-12-31 | -176,189,000 | USD | 2026-03-26 |
| Basic weighted-average shares | 2025-01-01 | 2025-12-31 | 1,646,208 | shares | 2026-03-26 |
| Diluted weighted-average shares | 2025-01-01 | 2025-12-31 | 1,646,208 | shares | 2026-03-26 |
| Basic earnings per share | 2025-01-01 | 2025-12-31 | -5.97 | USD/shares | 2026-03-26 |
| Diluted earnings per share | 2025-01-01 | 2025-12-31 | -5.97 | USD/shares | 2026-03-26 |
| Net property, plant and equipment | At date | 2025-12-31 | 5,000 | USD | 2026-03-26 |
| Share-based compensation expense | 2025-01-01 | 2025-12-31 | 340,000 | USD | 2026-03-26 |
| Operating income or loss | 2025-01-01 | 2025-12-31 | -9,950,000 | USD | 2026-03-26 |
| Current assets | At date | 2025-12-31 | 9,440,000 | USD | 2026-03-26 |
| Current liabilities | At date | 2025-12-31 | 2,731,000 | USD | 2026-03-26 |
| Operating expenses | 2025-01-01 | 2025-12-31 | 10,355,000 | USD | 2026-03-26 |
| Selling, general and administrative expense | 2022-01-01 | 2022-12-31 | 263,000 | USD | 2023-03-30 |
| Research and development expense | 2025-01-01 | 2025-12-31 | 6,693,000 | USD | 2026-03-26 |
Inspect the source
- Entity
- Can-Fite BioPharma Ltd. / CIK 0001536196
- Captured
- 2026-09-20T09:17:01.019Z
- SEC response SHA-256
6b71e874ffdef15c19b99ed81e159a170e416c2d6e6f6f9c176c37a11b34034c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001536196.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))